



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	Ophthalmology Research: An international Journal
Manuscript Number:	MS: 2012/ OR/ 2442
Title of the Manuscript:	Formulation and physical characterization of a novel sustained-release ophthalmic delivery system for sparfloxacin: the effect of the biological environment

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
1.The conflict in the old and new data of the phase solubility diagram might indicate lack of accuracy in the present work. In addition, this will give different formation constant (K_{11}) value. The author needs to be more accurate on constructing the phase solubility diagram to have accurate K_{11} and to compare with the result obtained by Chao J .	1-Phase solubility diagram was deleted in both method and results from the manuscript. However, both old and new data were exactly the same at all cyclodextrin concentration used, the only different was that, the new one had a point at cyclodextrin molar concentration equals 9 as shown in the figure .
2.Again, to prove complex formation and suitability of the analysis techniques (DSC, IR, and SEM), the author needs to prepare the physical mixture after treating each component (Drug, CD) separately with the same spray-dried procedure.	2- The only prepared and studied physical mixture was that mentioned in the submitted manuscript. Sorry, I can not prepare the required physical mixture now as I finished the practical part for my Ph D in U.K and returned back to my University in Egypt. We have not the same chemicals or instruments to conduct the required experiments at this moment.
3.The author needs to run also the dissolution using physical mixture prepared from spray-dried drug and CD.	3- The only mentioned dissolution study that has been done, I can not perform the required experiment now for the same reasons mentioned in 2.
4.Again, gel formulations in the present work can be done by simple procedure without using spray drying any more. So I recommend to prepare the same formulas (FM1, FM2, FM3 and FM4) using non-treated components (Drug and CD).	4- Your advices are very important to me and kept in mind in my future studies.
5.Does the novel formulation proposed by the present work offer a sustained-release? It is worthy to run dissolution profile as done by Gupta 2010. No enough discussion on this issue in the manuscript.	5- <i>In-vitro</i> release study using membranless has been included to the paper to indicate the sustained release of sparfloxacin from the thermosetting gels compared to the control.
6.By the way, heating rate in DSC might affect the extent of complex formation.	6- The heating rate used in my study was fixed all over the experiment. I did not study the effect of changing the heating rate on complex formation.